Clinical Study
Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice
Table 2
Activity and efficacy of sorafenib.
| | Intent-to-treat Analysis | | Number | % |
| Enrolled patients | 10 | 100 | Evaluable patients | 9 | 90 | Objective response
| 2 | 22 (CI ± 29) | Partial response
| 2 | 22 | Complete response | — | — | Stable disease | 6 | 67 | Progressive disease | 1 | 11 | Median progression-free survival, months | 7 | | Range | 2–34 | | Progression events | 8 | 80 | Median overall survival, months | 9 | | Range | 4–35+ | | Deaths | 7 | 70 |
|
|